A class action lawsuit has been filed against Ardent Health, Inc., alleging the healthcare company issued materially false and misleading financial guidance in its third quarter 2025 earnings. According to the complaint, Ardent overstated revenue due to inadequate accounts receivable assessments following the implementation of a new accounting system, while also inflating 2025 EBITDA guidance by approximately $57.5 million.
The litigation centers on the company's failure to properly account for industry-wide cost pressures and payer denials when establishing its financial projections. The defendants are accused of knowingly or recklessly disregarding these material factors that significantly impacted the company's financial performance, thereby deceiving investors about Ardent's true operational and financial condition.
Investors who purchased Ardent Health securities between July 18, 2024, and November 12, 2025, are eligible to participate in the class action. The law firm Bronstein, Gewirtz & Grossman LLC is urging affected shareholders to take action to preserve their legal rights and pursue potential recoveries for investment losses sustained as a result of the alleged misstatements.